Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

THE European Medicines Agency on Friday recommended authorizing a twice-yearly injectable drug “lenacapavir” to prevent HIV and help end the virus’ transmission. In a statement, the EU drug regulator ...

Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don't require a daily oral pill and ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

Lenacapavir had been approved in 2022 to treat certain HIV infections and, in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a recent licensing agreement ensuring accelerated access to countries in need.

Lenacapavir had been approved in 2022 to treat certain HIV infections and, in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23 ...

Lenacapavir had been approved in 2022 to treat certain HIV infections and, in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection ...